{"entity":{"id":"interstitial-lung-disease-on-antibody-drug-conjugates-and-targeted-drugs","kind":"protocol","name":"Interstitial lung disease on antibody-drug conjugates and targeted drugs: monitoring and management by grade","aka":["drug-induced ILD","drug-induced pneumonitis","trastuzumab deruxtecan ILD","T-DXd pneumonitis","Enhertu lung inflammation","osimertinib pneumonitis","everolimus non-infectious pneumonitis","CDK4/6 inhibitor pneumonitis","DIILD"],"tldr":"Some cancer drugs, above all trastuzumab deruxtecan, can inflame the lungs. It can show on a scan before there are any symptoms, and it is treated by pausing or stopping the drug and, often, steroids. The rules differ from drug to drug. A new or worsening cough, breathlessness or fever needs a call to your cancer team straight away, not at the next appointment.","summary":"Drug-induced ILD is a diagnosis of exclusion: infection, cancer progression, radiation pneumonitis and fluid overload look similar on CT. Grade 1 is a scan finding with no symptoms, grade 2 mild symptoms, grade 3 severe symptoms or a need for oxygen, grade 4 life-threatening. What happens at each grade depends on the drug, and the label of the drug being taken is the rule; the reader's own team's protocol comes first.\n\nHow common (US labels): trastuzumab deruxtecan 12% at 5.4 mg/kg, fatal in 0.9%, median onset 5.5 months; datopotamab deruxtecan 7% in lung cancer and 3.0% in breast cancer; osimertinib 4%; abemaciclib about 3%; ribociclib 1.6% in advanced breast cancer; everolimus up to 19%; sotorasib 2.2%; olaparib 1.0%. In a manufacturer-funded pooled analysis of 1150 trial patients on trastuzumab deruxtecan, 87.0% of first events came within 12 months, and the factors potentially associated with higher risk were age under 65, enrolment in Japan, a dose above 6.4 mg/kg, oxygen saturation below 95%, moderate or severe renal impairment, lung comorbidities and more than 4 years since diagnosis.\n\nGrade 1 (no symptoms), side by side. Trastuzumab deruxtecan and datopotamab deruxtecan: withhold until fully resolved, consider prednisolone at 0.5 mg/kg/day or more, and resume at the same dose if resolved within 28 days or one dose level lower if later. Everolimus: continue without changing the dose. Abemaciclib: no dose change at grade 1 or 2. Ribociclib: no interruption at grade 1. Osimertinib: stop permanently once ILD is confirmed, whatever the grade, except after recent chemoradiotherapy, where grade 1 may be continued or interrupted and restarted. Sotorasib and olaparib: withhold on suspicion and stop permanently if confirmed.\n\nGrade 2 and above. Deruxtecan conjugates: stop permanently and start prednisolone at 1 mg/kg/day or more for at least 14 days, then taper over at least 4 weeks. Osimertinib, sotorasib, olaparib: stopped. Everolimus: withhold at grade 2 or 3 and resume at half dose after improvement, stop at grade 4. Abemaciclib: withhold for persistent or recurrent grade 2 and resume one dose lower, stop at grade 3 or 4. Ribociclib: interrupt at grade 2 and consider a lower dose, stop at grade 3 or 4.\n\nThe expert opinion of Conte and colleagues (ESMO Open 2022, funded by Daiichi Sankyo and AstraZeneca, ungraded) adds a work-up (high-resolution CT at once, oxygen saturation, bloods, microbiology, lung function, bronchoscopy when the picture is unclear), prednisone 1 to 2 mg/kg/day at grade 2, methylprednisolone 1 to 2 mg/kg/day at grade 3, pulsed methylprednisolone 500 to 1000 mg/day for 3 days as an option at grade 4, and says infliximab, tocilizumab, mycophenolate or intravenous immunoglobulin may be considered at grade 3 if there is no improvement within 48 to 72 hours (at grade 4, infliximab, mycophenolate or immunoglobulin after 48 hours without improvement). It says the efficacy of steroids is not clearly established.","asOf":"2026-11-17","links":[],"tags":[],"related":["irae-pneumonitis","pneumocystis-pneumonia-prophylaxis","ild-overlap-caution","methylprednisolone"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-deruxtecan","datopotamab-deruxtecan","osimertinib","abemaciclib","ribociclib","everolimus","sotorasib","olaparib"],"companies":[],"institutions":[],"pathways":[],"terms":["ild","pneumonitis","radiation-pneumonitis","ctcae-grading"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"simple":"A few cancer medicines can inflame the lungs. Tell your cancer team straight away if you get a new cough, feel short of breath or have a fever. They may do a scan, pause the medicine and give steroids. Your own team's plan comes first.","domain":"symptom-management","setting":{"who":["doctor","nurse","pharmacist","patient-or-carer","multidisciplinary-team"],"where":["outpatient-clinic","chemotherapy-day-unit","acute-oncology-service","telephone-triage","emergency-department","ward"]},"population":"Adults taking a non-immunotherapy anticancer drug whose label warns of interstitial lung disease or pneumonitis: here trastuzumab deruxtecan, datopotamab deruxtecan, osimertinib, abemaciclib, ribociclib, everolimus, sotorasib and olaparib, whose US labels were read. Pneumonitis from checkpoint inhibitors and radiation pneumonitis have their own pages. Patritumab deruxtecan, ifinatamab deruxtecan and other products were not read label by label. Children are not addressed.","trigger":"Starting one of these drugs (baseline assessment and teaching), a new or worsening cough, breathlessness, fever or fall in oxygen saturation during treatment, or new lung shadowing on a scan done for any reason.","steps":[{"action":"Before the first dose, review the risk: existing lung disease, earlier drug-induced lung inflammation, kidney function and other medicines that can injure the lung","why":"The panel asks for the risk to be weighed before any anticancer drug is started. In the pooled trastuzumab deruxtecan trials, existing lung conditions and moderate or severe kidney impairment were among the factors potentially linked with a higher risk.","source":"conte-esmo-2022","quote":"Before the start of any anticancer therapy, physicians should carefully evaluate the risk for DIILD"},{"action":"For a drug with a high risk, record a baseline: oxygen saturation and other vital signs, a chest examination, chest imaging and spirometry","why":"A later change can only be judged against where the person started.","source":"conte-esmo-2022","quote":"(ii) the baseline evaluation of respiratory function (i.e. spirometry) in addition to vital signs, physical examination and chest imaging"},{"action":"Teach the person to report a new or worsening cough, breathlessness or fever straight away","why":"The label asks for these symptoms to be investigated promptly, and the expert panel says that finding the inflammation early could favour a better outcome.","source":"label-trastuzumab-deruxtecan","quote":"Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms."},{"action":"Throughout treatment, watch for cough, breathlessness, low oxygen levels and new lung changes on scans","why":"The expert panel says up to a third of people with drug-induced ILD have no symptoms, so it may be found on a scan. In the pooled trastuzumab deruxtecan trials, reviewers dated the onset earlier than the treating doctor had for 53.2% of events.","source":"label-abemaciclib","quote":"Monitor patients for pulmonary symptoms indicative of ILD or pneumonitis. Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams."},{"action":"If lung inflammation is suspected on ribociclib, datopotamab deruxtecan, sotorasib, olaparib or (outside the chemoradiotherapy setting) osimertinib, withhold the drug while it is assessed","why":"These labels each say to interrupt or withhold on suspicion. The everolimus label continues treatment when there are few or no symptoms, and the abemaciclib label asks for no change at grade 1.","source":"label-ribociclib","quote":"In patients who have new or worsening respiratory symptoms suspected to be due to ILD or pneumonitis, interrupt KISQALI immediately and evaluate the patient."},{"action":"Measure oxygen saturation and breathing rate, and confirm a low reading with an arterial blood gas","why":"The panel says a comparison with the person's own earlier values is always decisive, because oxygen levels can fall while still inside the normal range.","source":"conte-esmo-2022","quote":"When DIILD is suspected, vital signs should be routinely monitored, particularly the respiratory rate to detect tachypnoea and oxygen saturation by pulse oximetry (SpO2), the latter being extremely relevant in patients with dyspnoea."},{"action":"Arrange a high-resolution CT scan of the chest straight away","why":"The panel calls high-resolution CT the most sensitive test for finding ILD from its early stages, and it can show how much of the lung is involved.","source":"conte-esmo-2022","quote":"HRCT is recommended immediately after the medical examination."},{"action":"Exclude infection, cancer and other causes before settling on the drug as the cause","why":"The expert panel lists infection, radiation pneumonitis, bleeding into the lung, fluid on the lung and, more rarely, cancer spreading through the lung as conditions that overlap with drug-induced ILD.","source":"label-abemaciclib","quote":"Infectious, neoplastic, and other causes for such symptoms should be excluded by means of appropriate investigations."},{"action":"Involve a lung specialist, and consider bronchoscopy with lavage when the diagnosis is unclear or there is no improvement","why":"Washings from the lung can find an infection, bleeding or cancer spread that a scan cannot tell apart from drug injury.","source":"conte-esmo-2022","quote":"BAL should be considered when there is a lack of clinical improvement on withdrawal of the causative drug, despite corticosteroid therapy, or when the differential diagnosis is inconclusive."},{"action":"Grade 1 (scan changes, no symptoms) on trastuzumab deruxtecan or datopotamab deruxtecan: withhold the drug until the scan has cleared and consider steroids","why":"The labels pause these drugs even when there are no symptoms. If it resolves within 28 days treatment restarts at the same dose, and if it takes longer, one dose level lower.","source":"label-trastuzumab-deruxtecan","quote":"For asymptomatic (Grade 1) ILD, consider corticosteroid treatment (e.g., ≥0.5 mg/kg/day prednisolone or equivalent). Withhold ENHERTU until recovery"},{"action":"On everolimus with scan changes and few or no symptoms: continue at the same dose","why":"The label notes that imaging appears to overestimate how often clinical pneumonitis occurs.","source":"label-everolimus","quote":"Continue AFINITOR/AFINITOR DISPERZ without dose alteration in patients who develop radiological changes suggestive of non-infectious pneumonitis and have few or no symptoms."},{"action":"On osimertinib, stop the drug permanently once lung inflammation is confirmed, at any grade, unless it follows recent chemoradiotherapy","why":"The label says lung inflammation from this drug can be severe and fatal, and it allows a restart only at grade 1 after recent chemoradiotherapy.","source":"label-osimertinib","quote":"Permanently discontinue TAGRISSO if ILD/pneumonitis is confirmed"},{"action":"Grade 2 or higher (any symptoms) on trastuzumab deruxtecan or datopotamab deruxtecan: stop the drug permanently","why":"This is the rule in the label's boxed warning. The labels give no way to restart either drug once there have been symptoms.","source":"label-trastuzumab-deruxtecan","quote":"Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis."},{"action":"For symptomatic inflammation (grade 2 or higher) on trastuzumab deruxtecan or datopotamab deruxtecan, start a systemic steroid promptly, for example prednisolone at 1 mg/kg a day or more or an equivalent, continue for at least 14 days, then reduce gradually over at least 4 weeks","why":"The labels give this as their example regimen. The expert panel says that tapering too fast may reactivate the disease, and also that how well steroids work is not clearly established.","source":"label-trastuzumab-deruxtecan","quote":"In cases of symptomatic ILD (Grade 2 or greater), promptly initiate systemic corticosteroid treatment (e.g., ≥1 mg/kg/day prednisolone or equivalent) and continue for at least 14 days followed by gradual taper for at least 4 weeks."},{"action":"On abemaciclib, withhold for grade 2 that persists or recurs and restart one dose lower; stop permanently at grade 3 or 4","why":"The label asks for no dose change at grade 1, or at grade 2 that settles within 7 days with supportive measures, and stops the drug in severe cases, some of which have been fatal.","source":"label-abemaciclib","quote":"Withhold or reduce dose for patients who develop persistent or recurrent Grade 2 ILD or pneumonitis. Permanently discontinue VERZENIO in all patients with Grade 3 or 4 ILD or pneumonitis"},{"action":"Grade 3: stop the drug for good, give oxygen if the oxygen level is low, and start methylprednisolone 1 to 2 mg/kg a day or an equivalent; if there is no improvement within 48 to 72 hours, a second immunosuppressant may be considered","why":"The panel says severe symptoms may lead to a hospital stay. For grade 4 it describes urgent hospital treatment with intravenous steroids (usually methylprednisolone or prednisolone 2 mg/kg a day, or a pulse of methylprednisolone 500 to 1000 mg a day for 3 days), oxygen and sometimes ventilation.","source":"conte-esmo-2022","quote":"In grade 3 DIILD, the timely and definitive discontinuation of the anticancer drug and the initiation of corticosteroid therapy at 1-2 mg/kg/day of methylprednisolone or equivalent are essential."},{"action":"Repeat the CT about 2 weeks after diagnosis, sooner or later as the person's course dictates","why":"The scan shows whether treatment is working and, for some drugs, whether treatment may restart.","source":"conte-esmo-2022","quote":"A follow-up CT scan should be repeated 2 weeks after the initial diagnosis of DIILD, although the time interval can be adjusted depending on the patient’s overall clinical course."}],"bestInClass":{"statement":"Teaching and immediate reporting of symptoms, high-resolution CT on suspicion, a hold on suspicion where the label asks for one, exclusion of infection and other causes, and then the product label's rule for the grade. The labels do not agree, and all are shown. At grade 1: deruxtecan conjugates are withheld until resolved with steroids considered; everolimus, abemaciclib and ribociclib continue; osimertinib, sotorasib and olaparib stop once ILD is confirmed (osimertinib may continue at grade 1 after chemoradiotherapy). At grade 2: deruxtecan conjugates stop permanently; everolimus and ribociclib are withheld and may resume at a lower dose after recovery; abemaciclib continues unless grade 2 persists or recurs, when it is withheld and resumed one dose lower. The expert opinion of Conte and colleagues (funded by Daiichi Sankyo and AstraZeneca; ungraded) advises stopping the causative drug at grade 1 in general, says continuation can be considered in selected cases for checkpoint inhibitors, mTOR inhibitors and, by its authors' own opinion, tyrosine kinase inhibitors, which is more permissive than the osimertinib label, and says steroids are not generally needed at grade 1, where the trastuzumab deruxtecan label says to consider them. No source read cites a randomised comparison of these rules.","sources":["label-trastuzumab-deruxtecan","label-datopotamab-deruxtecan","label-osimertinib","label-abemaciclib","label-ribociclib","label-everolimus","label-sotorasib","label-olaparib","conte-esmo-2022"]},"variants":[{"name":"Grade 1 (no symptoms): hold, continue or stop, by drug","differs":"Trastuzumab deruxtecan and datopotamab deruxtecan: withhold until resolved to grade 0; same dose if resolved in 28 days or less, one dose level lower if longer; consider corticosteroids. Everolimus: continue without dose alteration. Abemaciclib: no dosage modification at grade 1 or 2. Ribociclib: no interruption; start appropriate medical therapy and monitor. Osimertinib: permanently discontinue if confirmed; after recent definitive platinum-based chemoradiotherapy, withhold or continue at grade 1 as clinically indicated. Sotorasib: withhold if suspected, permanently discontinue if confirmed and no other cause is found. Olaparib: interrupt if suspected, discontinue if confirmed.","evidence":"Regulatory labels, each from its own trials. The everolimus label notes that imaging appears to overestimate the incidence of clinical pneumonitis. Conte and colleagues say that no robust scientific evidence is available to guide the decision to continue at grade 1.","sources":["label-trastuzumab-deruxtecan","label-datopotamab-deruxtecan","label-everolimus","label-abemaciclib","label-ribociclib","label-osimertinib","label-sotorasib","label-olaparib","conte-esmo-2022"]},{"name":"Grade 2 and above: permanent stop or a lower dose, by drug","differs":"Deruxtecan conjugates: permanently discontinue at grade 2 or higher. Osimertinib: permanently discontinue at grade 2 or higher in every setting. Everolimus: withhold at grade 2 until grade 0 or 1 and resume at 50% of the previous dose, stopping if there is no improvement within 4 weeks; the same at grade 3, stopping if grade 3 recurs; stop at grade 4. Abemaciclib: withhold for grade 2 that does not resolve within 7 days with maximal supportive measures, or recurs, and resume at the next lower dose; discontinue at grade 3 or 4. Ribociclib: interrupt at grade 2 until grade 1 or less and consider the next lower dose, stopping if grade 2 recurs; discontinue at grade 3 or 4.","evidence":"Regulatory labels. Conte and colleagues (ungraded expert opinion, funded by Daiichi Sankyo and AstraZeneca) say that in most cases the drug should be stopped permanently after grade 2, and that rechallenge should be considered if the drug had given remarkable benefit, the ILD has resolved completely on symptoms and scan, risk factors for recurrence are limited, and the drug is a checkpoint inhibitor, an mTOR inhibitor or one of most targeted agents, but not trastuzumab deruxtecan.","sources":["label-trastuzumab-deruxtecan","label-datopotamab-deruxtecan","label-osimertinib","label-everolimus","label-abemaciclib","label-ribociclib","conte-esmo-2022"]},{"name":"Steroid dose and length","differs":"Trastuzumab deruxtecan and datopotamab deruxtecan labels: consider prednisolone 0.5 mg/kg/day or more at grade 1; 1 mg/kg/day or more at grade 2 or higher for at least 14 days, then a taper over at least 4 weeks. Conte and colleagues: steroids not generally needed at grade 1 (0.5 mg/kg/day of prednisone or equivalent should be considered if steroids are judged appropriate, as with trastuzumab deruxtecan, then a taper over at least 4 weeks); prednisone 1 to 2 mg/kg/day at grade 2, tapered over 4 to 6 weeks in those who respond well; methylprednisolone 1 to 2 mg/kg/day at grade 3 with a taper after 8 to 12 weeks; severe pneumonia is usually treated with intravenous methylprednisolone or prednisolone 2 mg/kg/day, and at grade 4 a pulse of methylprednisolone 500 to 1000 mg/day for 3 days, followed by prednisolone 1 to 2 mg/kg/day for 2 to 4 weeks, should also be considered. For people on trastuzumab deruxtecan the panel repeats the label's 1 mg/kg/day or more of prednisolone at grades 2 and 3. Everolimus label: corticosteroids may be indicated until symptoms resolve, with Pneumocystis prophylaxis while they are given. The other labels read give no steroid dose.","evidence":"No controlled trial of steroid dose or duration in drug-induced ILD was cited by any source read. Conte and colleagues state that the efficacy of corticosteroids is not clearly established.","sources":["label-trastuzumab-deruxtecan","label-datopotamab-deruxtecan","label-everolimus","conte-esmo-2022"]},{"name":"Restarting trastuzumab deruxtecan after grade 1","differs":"The label allows a restart once a grade 1 event has resolved to grade 0. In the pooled trials fewer than a quarter of such patients were retreated.","evidence":"A pooled analysis of nine trials (Rugo and colleagues 2025, abstract read; funders listed as AstraZeneca and Daiichi Sankyo): of 193 patients with a grade 1 event, 45 (23.3%) were retreated; ILD came back in 15 (33.3%), all grade 1 or 2, at a median of 64 days. Uncontrolled, and the retreated patients were selected.","sources":["label-trastuzumab-deruxtecan","rugo-2025"]},{"name":"Osimertinib after chemoradiotherapy","differs":"For people who have had recent definitive platinum-based chemoradiotherapy, the label allows osimertinib to be continued, or interrupted and restarted, at grade 1; everyone else stops permanently once ILD is confirmed.","evidence":"In the LAURA study ILD or pneumonitis, including radiation pneumonitis, was reported in 56% of 143 patients on osimertinib and 38% of 73 on placebo; of 46 patients rechallenged, 11% had a recurrence (label).","sources":["label-osimertinib"]}],"grades":[{"claim":"Trastuzumab deruxtecan: permanent stop at grade 2 or higher (boxed warning)","grade":"Regulatory label; not graded","source":"label-trastuzumab-deruxtecan","quote":"Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis."},{"claim":"Datopotamab deruxtecan: withhold on suspicion, permanent stop if grade 2 or higher is confirmed","grade":"Regulatory label; not graded","source":"label-datopotamab-deruxtecan","quote":"Withhold DATROWAY in patients with suspected ILD/pneumonitis and permanently discontinue DATROWAY if ≥Grade 2 ILD/pneumonitis is confirmed"},{"claim":"Osimertinib after chemoradiotherapy: grade 1 may continue or be interrupted and restarted","grade":"Regulatory label; not graded","source":"label-osimertinib","quote":"For patients who have received recent definitive platinum-based chemoradiation therapy with Grade 1 ILD/pneumonitis continue TAGRISSO or interrupt and restart, as appropriate."},{"claim":"Everolimus: withhold or stop for grade 2 to 4, with Pneumocystis prophylaxis when steroids are needed","grade":"Regulatory label; not graded","source":"label-everolimus","quote":"Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required."},{"claim":"Ribociclib: no interruption at grade 1","grade":"Regulatory label; not graded","source":"label-ribociclib","quote":"No dose interruption or adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated."},{"claim":"Sotorasib: withhold on suspicion, stop permanently if no other cause is found","grade":"Regulatory label; not graded","source":"label-sotorasib","quote":"Withhold LUMAKRAS if ILD/pneumonitis is suspected."},{"claim":"Olaparib: interrupt on suspicion, discontinue if confirmed","grade":"Regulatory label; not graded","source":"label-olaparib","quote":"If pneumonitis is confirmed, discontinue Lynparza treatment and treat the patient appropriately."},{"claim":"At grade 1, continuation can be considered for mTOR inhibitors and, in the authors' opinion, tyrosine kinase inhibitors; antibody-drug conjugates should be stopped until resolution","grade":"Expert opinion; not graded (funded by Daiichi Sankyo and AstraZeneca)","source":"conte-esmo-2022","quote":"Specifically, continuation can be considered for ICIs and mTOR inhibitors (and also tyrosine kinase inhibitors by our expert opinion), whereas ADCs such as T-DXd should be discontinued until resolution."},{"claim":"Steroids are not generally needed at grade 1","grade":"Expert opinion; not graded (funded by Daiichi Sankyo and AstraZeneca)","source":"conte-esmo-2022","quote":"Steroid therapy is not generally needed for grade 1 DIILD; moreover, steroids may have a negative impact on survival if the patient is treated with ICIs."},{"claim":"The efficacy of corticosteroids is not clearly established","grade":"Expert opinion; not graded (funded by Daiichi Sankyo and AstraZeneca)","source":"conte-esmo-2022","quote":"The efficacy of corticosteroids is not clearly established, given the widespread practice of discontinuing the pneumotoxic drug when starting steroid therapy."},{"claim":"Treatment need not wait for every other cause to be excluded in severe cases","grade":"Expert opinion; not graded (funded by Daiichi Sankyo and AstraZeneca)","source":"conte-esmo-2022","quote":"Since early treatment of DIILD is critical for improved outcome, a definitive diagnosis (by means of exclusion of all the alternative aetiologies) is not always mandatory before the start of steroid treatment, especially in severe cases (grade 3 and 4)."},{"claim":"Too fast a steroid taper can reactivate the disease","grade":"Expert opinion; not graded (funded by Daiichi Sankyo and AstraZeneca)","source":"conte-esmo-2022","quote":"Early interruption of steroid treatment or an excessively fast tapering may reactivate the disease."},{"claim":"Most first events on trastuzumab deruxtecan come in the first 12 months","grade":"Pooled analysis of trials; not graded (supported by AstraZeneca and Daiichi Sankyo)","source":"powell-2022","quote":"Overall, 87.0% (154/177) had a first adjudicated drug-related ILD/pneumonitis event within 12 months of starting T-DXd"},{"claim":"ILD recurred in a third of patients retreated with trastuzumab deruxtecan after grade 1, all grade 1 or 2","grade":"Pooled analysis of trials; not graded (funders listed as AstraZeneca and Daiichi Sankyo)","source":"rugo-2025","quote":"ILD recurred in one-third of patients; all recurrence events were grade 1/2 and manageable using existing treatment guidelines."}],"sources":[{"key":"conte-esmo-2022","label":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment (funded by Daiichi Sankyo and AstraZeneca)","publisher":"ESMO Open (Conte et al.; a panel of 14 Italian experts, not an ESMO guideline; publication, workshops and medical writing funded by Daiichi Sankyo S.p.A. and AstraZeneca S.p.A.)","year":2022,"url":"https://doi.org/10.1016/j.esmoop.2022.100404","doi":"10.1016/j.esmoop.2022.100404","gradingScheme":"Expert opinion from a literature review and panel meetings; no levels of evidence or grades are printed.","read":"full-text","accessed":"2026-11-17"},{"key":"powell-2022","label":"Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies (supported by AstraZeneca and Daiichi Sankyo)","publisher":"ESMO Open (Powell et al.; supported by AstraZeneca and Daiichi Sankyo, medical writing funded by AstraZeneca)","year":2022,"url":"https://doi.org/10.1016/j.esmoop.2022.100554","doi":"10.1016/j.esmoop.2022.100554","gradingScheme":"A pooled analysis of trial data; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"swain-2022","label":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis: focus on proactive monitoring, diagnosis, and management","publisher":"Cancer Treatment Reviews (Swain et al.; Europe PMC lists AstraZeneca among the funders; the paper's own funding statement was not read)","year":2022,"url":"https://doi.org/10.1016/j.ctrv.2022.102378","doi":"10.1016/j.ctrv.2022.102378","gradingScheme":"Not graded, as far as the abstract shows.","read":"abstract","accessed":"2026-11-17"},{"key":"rugo-2025","label":"Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis","publisher":"Annals of Oncology (Rugo et al.; Europe PMC lists AstraZeneca and Daiichi Sankyo as funders)","year":2025,"url":"https://doi.org/10.1016/j.annonc.2025.07.015","doi":"10.1016/j.annonc.2025.07.015","gradingScheme":"A pooled analysis of trial data; not graded.","read":"abstract","accessed":"2026-11-17"},{"key":"label-trastuzumab-deruxtecan","label":"Enhertu (fam-trastuzumab deruxtecan-nxki) for injection: US prescribing information","publisher":"Daiichi Sankyo, on DailyMed (US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e67e73e-ddf4-4e4d-8b50-09d7514910b6","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"label-datopotamab-deruxtecan","label":"Datroway (datopotamab deruxtecan) for injection: US prescribing information","publisher":"Daiichi Sankyo, on DailyMed (US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2950227c-6230-4ca4-a135-46e44d9424a0","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"label-osimertinib","label":"Tagrisso (osimertinib) tablets: US prescribing information","publisher":"AstraZeneca, on DailyMed (US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"label-abemaciclib","label":"Verzenio (abemaciclib) tablets: US prescribing information","publisher":"Eli Lilly, on DailyMed (US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"label-ribociclib","label":"Kisqali (ribociclib) tablets: US prescribing information","publisher":"Novartis, on DailyMed (US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"label-everolimus","label":"Afinitor and Afinitor Disperz (everolimus): US prescribing information","publisher":"Novartis, on DailyMed (US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2150f73a-179b-4afc-b8ce-67c85cc72f04","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"label-sotorasib","label":"Lumakras (sotorasib) tablets: US prescribing information","publisher":"Amgen, on DailyMed (US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c80a362c-7ac3-4894-a076-0691e68ef8c1","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"label-olaparib","label":"Lynparza (olaparib) tablets: US prescribing information","publisher":"AstraZeneca, on DailyMed (US National Library of Medicine)","year":2025,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"}],"upgrades":[],"gaps":["No graded guideline on drug-induced ILD from targeted drugs or antibody-drug conjugates was read. The one management paper read in full (Conte and colleagues, ESMO Open 2022) is the ungraded opinion of an Italian expert panel, paid for by Daiichi Sankyo and AstraZeneca, the companies that market trastuzumab deruxtecan, with an employee of each thanked for contributing to the conception and design of the work.","The multidisciplinary guidance for trastuzumab deruxtecan (Swain and colleagues, 2022) was read as an abstract only: on 17 November 2026 the publisher's page again gave a script no full text and Europe PMC holds none. Its schedule for routine CT scans during treatment is therefore not given here, and no label read sets one. How often to scan a person with no symptoms is not settled by anything read in full.","Steroid dose and duration rest on label wording ('e.g.') and expert opinion. Conte and colleagues state that the efficacy of corticosteroids is not clearly established, and no source read cites a controlled trial.","At grade 1 the sources disagree and none rests on a comparison: the trastuzumab deruxtecan label withholds, the everolimus and CDK4/6 inhibitor labels continue, the osimertinib label stops permanently outside the chemoradiotherapy setting, while Conte and colleagues would allow selected continuation on tyrosine kinase inhibitors by their own opinion.","Retreatment with trastuzumab deruxtecan after grade 1 was read as an abstract only (Rugo and colleagues 2025); the patients retreated were a selected 23.3%, and the analysis has manufacturer funders. Europe PMC lists an erratum to this paper (Annals of Oncology, 2026, doi 10.1016/j.annonc.2025.12.001), which on 17 November 2026 could not be read, so the retreatment figures here are those of the original abstract. There are no data read here on retreatment after grade 2, which the label forbids.","Patritumab deruxtecan, ifinatamab deruxtecan and trastuzumab rezetecan record ILD in this corpus but no label or guideline covering them was read; they are not listed among this protocol's drugs. The other EGFR inhibitors (gefitinib, erlotinib, afatinib), palbociclib and the other PARP inhibitors were not read label by label.","The Japanese Respiratory Society consensus on drug-induced lung injury and any ASCO guidance were not read. European product information was not read and may differ from the US labels.","The risk factors for trastuzumab deruxtecan ILD come from one exploratory, manufacturer-funded pooled analysis whose authors say they need confirmation. The supplementary table of risk factors in Conte and colleagues was not read.","The labels read say to report symptoms 'immediately' (trastuzumab deruxtecan, osimertinib) or 'promptly' (everolimus). No source read sets a time limit such as the same day, and none says which symptoms need an emergency call rather than a call to the cancer team.","Europe PMC lists three later papers that were not read: an expert consensus from China on ILD from HER2 antibody-drug conjugates (Cancer, 2024), a Chinese expert consensus on anticancer drug-induced ILD (Current Medical Science, 2023) and a critical appraisal of guidelines and consensus statements on anticancer drug-induced ILD (Expert Opinion on Drug Safety, 2026). No newer edition of the Conte or Swain papers was found on 17 November 2026."]},"route":"/protocols/interstitial-lung-disease-on-antibody-drug-conjugates-and-targeted-drugs/","neighbours":{"protocol":[{"id":"breathlessness-and-cough-during-anticancer-treatment","kind":"protocol","name":"Breathlessness and cough during anticancer drug treatment: what is excluded first and how the symptom is eased","route":"/protocols/breathlessness-and-cough-during-anticancer-treatment/"},{"id":"irae-pneumonitis","kind":"protocol","name":"Immune-related pneumonitis from checkpoint inhibitors, by grade","route":"/protocols/irae-pneumonitis/"},{"id":"pneumocystis-pneumonia-prophylaxis","kind":"protocol","name":"Pneumocystis pneumonia (PJP) prophylaxis with co-trimoxazole","route":"/protocols/pneumocystis-pneumonia-prophylaxis/"}],"pairing":[{"id":"ild-overlap-caution","kind":"pairing","name":"Caution: DXd ADC + agents with pneumonitis risk","route":"/pairings/ild-overlap-caution/"}],"drug":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/"},{"id":"methylprednisolone","kind":"drug","name":"Methylprednisolone","route":"/drugs/methylprednisolone/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"term":[{"id":"ctcae-grading","kind":"term","name":"CTCAE toxicity grading (grade 3-4 adverse events)","route":"/terms/ctcae-grading/"},{"id":"ild","kind":"term","name":"Interstitial lung disease (ILD) / pneumonitis","route":"/terms/ild/"},{"id":"pneumonitis","kind":"term","name":"Pneumonitis","route":"/terms/pneumonitis/"},{"id":"radiation-pneumonitis","kind":"term","name":"Radiation pneumonitis and lung fibrosis","route":"/terms/radiation-pneumonitis/"}]}}